ID   DLDH_HUMAN              Reviewed;         509 AA.
AC   P09622; B2R5X0; B4DHG0; B4DT69; Q14131; Q14167; Q59EV8; Q8WTS4;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 2.
DT   10-MAY-2017, entry version 213.
DE   RecName: Full=Dihydrolipoyl dehydrogenase, mitochondrial;
DE            EC=1.8.1.4 {ECO:0000269|PubMed:15712224, ECO:0000269|PubMed:16442803, ECO:0000269|PubMed:16770810, ECO:0000269|PubMed:17404228, ECO:0000269|PubMed:20160912, ECO:0000269|PubMed:20385101};
DE   AltName: Full=Dihydrolipoamide dehydrogenase;
DE   AltName: Full=Glycine cleavage system L protein;
DE   Flags: Precursor;
GN   Name=DLD; Synonyms=GCSL, LAD, PHE3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-104.
RX   PubMed=3693355;
RA   Otulakowski G., Robinson B.H.;
RT   "Isolation and sequence determination of cDNA clones for porcine and
RT   human lipoamide dehydrogenase. Homology to other disulfide
RT   oxidoreductases.";
RL   J. Biol. Chem. 262:17313-17318(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=3278312; DOI=10.1073/pnas.85.5.1422;
RA   Pons G., Raefsky-Estrin C., Carothers D.J., Pepin R.A., Javed A.A.,
RA   Jesse B.W., Ganapathi M.K., Samols D., Patel M.S.;
RT   "Cloning and cDNA sequence of the dihydrolipoamide dehydrogenase
RT   component human alpha-ketoacid dehydrogenase complexes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:1422-1426(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT THR-104.
RC   TISSUE=Liver;
RX   PubMed=8406489; DOI=10.1006/geno.1993.1335;
RA   Feigenbaum A.S., Robinson B.H.;
RT   "The structure of the human dihydrolipoamide dehydrogenase gene (DLD)
RT   and its upstream elements.";
RL   Genomics 17:376-381(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Brain, Brain cortex, and Pericardium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-13.
RX   PubMed=1332063; DOI=10.1073/pnas.89.22.10964;
RA   Johanning G.L., Morris J.I., Madhusudhan K.T., Samols D., Patel M.S.;
RT   "Characterization of the transcriptional regulatory region of the
RT   human dihydrolipoamide dehydrogenase gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:10964-10968(1992).
RN   [11]
RP   SUBUNIT.
RX   PubMed=14638692; DOI=10.1074/jbc.M308172200;
RA   Hiromasa Y., Fujisawa T., Aso Y., Roche T.E.;
RT   "Organization of the cores of the mammalian pyruvate dehydrogenase
RT   complex formed by E2 and E2 plus the E3-binding protein and their
RT   capacities to bind the E1 and E3 components.";
RL   J. Biol. Chem. 279:6921-6933(2004).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=15888450; DOI=10.1074/jbc.M500310200;
RA   Mitra K., Rangaraj N., Shivaji S.;
RT   "Novelty of the pyruvate metabolic enzyme dihydrolipoamide
RT   dehydrogenase in spermatozoa: correlation of its localization,
RT   tyrosine phosphorylation, and activity during sperm capacitation.";
RL   J. Biol. Chem. 280:25743-25753(2005).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, CHARACTERIZATION OF
RP   VARIANT DLDD ASP-479, AND MUTAGENESIS OF GLU-466; HIS-485 AND SER-491.
RX   PubMed=17404228; DOI=10.1073/pnas.0610618104;
RA   Babady N.E., Pang Y.P., Elpeleg O., Isaya G.;
RT   "Cryptic proteolytic activity of dihydrolipoamide dehydrogenase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:6158-6163(2007).
RN   [14]
RP   CATALYTIC ACTIVITY, INTERACTION WITH PDHX, MUTAGENESIS OF LYS-89;
RP   ARG-482; GLU-492 AND LYS-505, AND CHARACTERIZATION OF VARIANTS DLDD
RP   GLU-72; LYS-375; LEU-488 AND GLY-495.
RX   PubMed=20160912; DOI=10.1016/j.molcatb.2009.05.001;
RA   Patel M.S., Korotchkina L.G., Sidhu S.;
RT   "Interaction of E1 and E3 components with the core proteins of the
RT   human pyruvate dehydrogenase complex.";
RL   J. Mol. Catal., B Enzym. 61:2-6(2009).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-143; LYS-410 AND LYS-417,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   CATALYTIC ACTIVITY, INTERACTION WITH PDHX, AND MUTAGENESIS OF HIS-383;
RP   ASP-448; TYR-473 AND ARG-482.
RX   PubMed=20385101; DOI=10.1016/j.bbrc.2010.04.038;
RA   Park Y.H., Patel M.S.;
RT   "Characterization of interactions of dihydrolipoamide dehydrogenase
RT   with its binding protein in the human pyruvate dehydrogenase
RT   complex.";
RL   Biochem. Biophys. Res. Commun. 395:416-419(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S.,
RA   Fischer-Posovszky P., Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion
RT   profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-502, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   CLEAVAGE OF TRANSIT PEPTIDE [LARGE SCALE ANALYSIS] AFTER TYR-35, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 36-509 IN COMPLEXES WITH NAD
RP   AND FAD, AND SUBUNIT.
RX   PubMed=15946682; DOI=10.1016/j.jmb.2005.05.014;
RA   Brautigam C.A., Chuang J.L., Tomchick D.R., Machius M., Chuang D.T.;
RT   "Crystal structure of human dihydrolipoamide dehydrogenase: NAD+/NADH
RT   binding and the structural basis of disease-causing mutations.";
RL   J. Mol. Biol. 350:543-552(2005).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.59 ANGSTROMS) OF 36-509.
RX   PubMed=16263718; DOI=10.1074/jbc.M507850200;
RA   Ciszak E.M., Makal A., Hong Y.S., Vettaikkorumakankauv A.K.,
RA   Korotchkina L.G., Patel M.S.;
RT   "How dihydrolipoamide dehydrogenase-binding protein binds
RT   dihydrolipoamide dehydrogenase in the human pyruvate dehydrogenase
RT   complex.";
RL   J. Biol. Chem. 281:648-655(2006).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.18 ANGSTROMS) OF 36-509 IN COMPLEX WITH PDHX,
RP   CATALYTIC ACTIVITY, AND CHARACTERIZATION OF VARIANT DLDD GLY-495.
RX   PubMed=16442803; DOI=10.1016/j.str.2006.01.001;
RA   Brautigam C.A., Wynn R.M., Chuang J.L., Machius M., Tomchick D.R.,
RA   Chuang D.T.;
RT   "Structural insight into interactions between dihydrolipoamide
RT   dehydrogenase (E3) and E3 binding protein of human pyruvate
RT   dehydrogenase complex.";
RL   Structure 14:611-621(2006).
RN   [25]
RP   CRYO-ELECTRON MICROSCOPY (33.3 ANGSTROMS) OF INNER CORE OF THE
RP   COMPLEX, AND SUBUNIT.
RX   PubMed=20361979; DOI=10.1016/j.jmb.2010.03.043;
RA   Vijayakrishnan S., Kelly S.M., Gilbert R.J., Callow P., Bhella D.,
RA   Forsyth T., Lindsay J.G., Byron O.;
RT   "Solution structure and characterisation of the human pyruvate
RT   dehydrogenase complex core assembly.";
RL   J. Mol. Biol. 399:71-93(2010).
RN   [26]
RP   VARIANTS DLDD GLU-72 AND LEU-488.
RX   PubMed=8506365; DOI=10.1073/pnas.90.11.5186;
RA   Liu T.-C., Kim H., Arizmendi C., Kitano A., Patel M.S.;
RT   "Identification of two missense mutations in a dihydrolipoamide
RT   dehydrogenase-deficient patient.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5186-5190(1993).
RN   [27]
RP   VARIANTS DLDD GLY-136 DEL AND LYS-375.
RX   PubMed=9540846; DOI=10.1016/S0925-4439(97)00073-2;
RA   Hong Y.S., Kerr D.S., Liu T.C., Lusk M., Powell B.R., Patel M.S.;
RT   "Deficiency of dihydrolipoamide dehydrogenase due to two mutant
RT   alleles (E340K and G101del). Analysis of a family and prenatal
RT   testing.";
RL   Biochim. Biophys. Acta 1362:160-168(1997).
RN   [28]
RP   VARIANT DLDD GLY-495.
RX   PubMed=8968745; DOI=10.1093/hmg/5.12.1925;
RA   Hong Y.S., Kerr D.S., Craigen W.J., Tan J., Pan Y., Lusk M.,
RA   Patel M.S.;
RT   "Identification of two mutations in a compound heterozygous child with
RT   dihydrolipoamide dehydrogenase deficiency.";
RL   Hum. Mol. Genet. 5:1925-1930(1996).
RN   [29]
RP   VARIANT DLDD VAL-479.
RX   PubMed=10448086; DOI=10.1006/bbrc.1999.1133;
RA   Shany E., Saada A., Landau D., Shaag A., Hershkovitz E., Elpeleg O.N.;
RT   "Lipoamide dehydrogenase deficiency due to a novel mutation in the
RT   interface domain.";
RL   Biochem. Biophys. Res. Commun. 262:163-166(1999).
RN   [30]
RP   VARIANTS DLDD VAL-361 AND LYS-375.
RX   PubMed=11687750;
RA   Cerna L., Wenchich L., Hansikova H., Kmoch S., Peskova K.,
RA   Chrastina P., Brynda J., Zeman J.;
RT   "Novel mutations in a boy with dihydrolipoamide dehydrogenase
RT   deficiency.";
RL   Med. Sci. Monit. 7:1319-1325(2001).
RN   [31]
RP   VARIANT DLDD THR-393.
RX   PubMed=12925875; DOI=10.1007/s00431-003-1282-z;
RA   Grafakou O., Oexle K., van den Heuvel L., Smeets R., Trijbels F.,
RA   Goebel H.H., Bosshard N., Superti-Furga A., Steinmann B., Smeitink J.;
RT   "Leigh syndrome due to compound heterozygosity of dihydrolipoamide
RT   dehydrogenase gene mutations. Description of the first E3 splice site
RT   mutation.";
RL   Eur. J. Pediatr. 162:714-718(2003).
RN   [32]
RP   VARIANT DLDD GLY-482, CHARACTERIZATION OF VARIANT DLDD GLY-482, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=15712224; DOI=10.1002/humu.9319;
RA   Odievre M.H., Chretien D., Munnich A., Robinson B.H., Dumoulin R.,
RA   Masmoudi S., Kadhom N., Roetig A., Rustin P., Bonnefont J.P.;
RT   "A novel mutation in the dihydrolipoamide dehydrogenase E3 subunit
RT   gene (DLD) resulting in an atypical form of alpha-ketoglutarate
RT   dehydrogenase deficiency.";
RL   Hum. Mutat. 25:323-324(2005).
RN   [33]
RP   VARIANTS DLDD THR-47; CYS-229 AND LYS-375, AND CATALYTIC ACTIVITY.
RX   PubMed=16770810; DOI=10.1002/ajmg.a.31313;
RA   Cameron J.M., Levandovskiy V., Mackay N., Raiman J., Renaud D.L.,
RA   Clarke J.T., Feigenbaum A., Elpeleg O., Robinson B.H.;
RT   "Novel mutations in dihydrolipoamide dehydrogenase deficiency in two
RT   cousins with borderline-normal PDH complex activity.";
RL   Am. J. Med. Genet. A 140:1542-1552(2006).
RN   [34]
RP   VARIANT DLDD CYS-229.
RX   PubMed=9934985;
RX   DOI=10.1002/(SICI)1096-8628(19990115)82:2<177::AID-AJMG15>3.0.CO;2-9;
RA   Shaag A., Saada A., Berger I., Mandel H., Joseph A., Feigenbaum A.,
RA   Elpeleg O.N.;
RT   "Molecular basis of lipoamide dehydrogenase deficiency in Ashkenazi
RT   Jews.";
RL   Am. J. Med. Genet. 82:177-182(1999).
CC   -!- FUNCTION: Lipoamide dehydrogenase is a component of the glycine
CC       cleavage system as well as an E3 component of three alpha-ketoacid
CC       dehydrogenase complexes (pyruvate-, alpha-ketoglutarate-, and
CC       branched-chain amino acid-dehydrogenase complex). In monomeric
CC       form has additional moonlighting function as serine protease
CC       (PubMed:17404228). Involved in the hyperactivation of spermatazoa
CC       during capacitation and in the spermatazoal acrosome reaction (By
CC       similarity). {ECO:0000250|UniProtKB:Q811C4,
CC       ECO:0000269|PubMed:17404228}.
CC   -!- CATALYTIC ACTIVITY: Protein N(6)-(dihydrolipoyl)lysine + NAD(+) =
CC       protein N(6)-(lipoyl)lysine + NADH. {ECO:0000269|PubMed:15712224,
CC       ECO:0000269|PubMed:16442803, ECO:0000269|PubMed:16770810,
CC       ECO:0000269|PubMed:17404228, ECO:0000269|PubMed:20160912,
CC       ECO:0000269|PubMed:20385101}.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:15946682,
CC         ECO:0000269|PubMed:16442803};
CC       Note=Binds 1 FAD per subunit. {ECO:0000269|PubMed:15946682,
CC       ECO:0000269|PubMed:16442803};
CC   -!- ENZYME REGULATION: Disruption of native heterodimer state inhibits
CC       primary dihydrolipoamide dehydrogenase activity and induces serine
CC       protease activity. {ECO:0000269|PubMed:17404228}.
CC   -!- SUBUNIT: Homodimer (PubMed:15946682). Part of the multimeric
CC       pyruvate dehydrogenase complex that contains multiple copies of
CC       pyruvate dehydrogenase (subunits PDH1A and PDHB, E1),
CC       dihydrolipoamide acetyltransferase (DLAT, E2) and lipoamide
CC       dehydrogenase (DLD, E3) (PubMed:14638692). These subunits are
CC       bound to an inner core composed of about 48 DLAT and 12 PDHX
CC       molecules (by non covalent bonds) (PubMed:14638692,
CC       PubMed:20361979). Interacts with PDHX (PubMed:20385101,
CC       PubMed:16442803, PubMed:20160912, PubMed:20361979).
CC       {ECO:0000269|PubMed:14638692, ECO:0000269|PubMed:15946682,
CC       ECO:0000269|PubMed:16442803, ECO:0000269|PubMed:20160912,
CC       ECO:0000269|PubMed:20361979, ECO:0000269|PubMed:20385101}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion matrix
CC       {ECO:0000305|PubMed:3693355}. Cytoplasmic vesicle, secretory
CC       vesicle, acrosome {ECO:0000269|PubMed:15888450}. Cell projection,
CC       cilium, flagellum {ECO:0000250|UniProtKB:Q811C4}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P09622-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P09622-2; Sequence=VSP_055855;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=P09622-3; Sequence=VSP_055856;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Tyrosine phosphorylated. {ECO:0000250|UniProtKB:Q811C4}.
CC   -!- DISEASE: Dihydrolipoamide dehydrogenase deficiency (DLDD)
CC       [MIM:246900]: An autosomal recessive metabolic disorder
CC       characterized biochemically by a combined deficiency of the
CC       branched-chain alpha-keto acid dehydrogenase complex (BCKDC),
CC       pyruvate dehydrogenase complex (PDC), and alpha-ketoglutarate
CC       dehydrogenase complex (KGDC). Clinically, affected individuals
CC       have lactic acidosis and neurologic deterioration due to
CC       sensitivity of the central nervous system to defects in oxidative
CC       metabolism. {ECO:0000269|PubMed:10448086,
CC       ECO:0000269|PubMed:11687750, ECO:0000269|PubMed:12925875,
CC       ECO:0000269|PubMed:15712224, ECO:0000269|PubMed:16442803,
CC       ECO:0000269|PubMed:16770810, ECO:0000269|PubMed:17404228,
CC       ECO:0000269|PubMed:20160912, ECO:0000269|PubMed:8506365,
CC       ECO:0000269|PubMed:8968745, ECO:0000269|PubMed:9540846,
CC       ECO:0000269|PubMed:9934985}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: The active site is a redox-active disulfide bond.
CC   -!- SIMILARITY: Belongs to the class-I pyridine nucleotide-disulfide
CC       oxidoreductase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92940.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J03490; AAA59527.1; -; mRNA.
DR   EMBL; J03620; AAA35764.1; -; mRNA.
DR   EMBL; L13761; AAB01381.1; -; Genomic_DNA.
DR   EMBL; L13749; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13750; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13751; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13752; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13753; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13754; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13748; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13755; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13759; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13760; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13756; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13757; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; L13758; AAB01381.1; JOINED; Genomic_DNA.
DR   EMBL; AK295080; BAG58122.1; -; mRNA.
DR   EMBL; AK300077; BAG61881.1; -; mRNA.
DR   EMBL; AK312346; BAG35267.1; -; mRNA.
DR   EMBL; AB209703; BAD92940.1; ALT_INIT; mRNA.
DR   EMBL; AC005046; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236947; EAL24389.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83421.1; -; Genomic_DNA.
DR   EMBL; BC018648; AAH18648.1; -; mRNA.
DR   EMBL; BC018696; AAH18696.1; -; mRNA.
DR   EMBL; M99384; AAA35759.1; -; Genomic_DNA.
DR   CCDS; CCDS5749.1; -. [P09622-1]
DR   CCDS; CCDS78268.1; -. [P09622-3]
DR   PIR; A92622; DEHULP.
DR   RefSeq; NP_000099.2; NM_000108.4. [P09622-1]
DR   RefSeq; NP_001276679.1; NM_001289750.1. [P09622-2]
DR   RefSeq; NP_001276680.1; NM_001289751.1.
DR   RefSeq; NP_001276681.1; NM_001289752.1. [P09622-3]
DR   UniGene; Hs.131711; -.
DR   PDB; 1ZMC; X-ray; 2.53 A; A/B/C/D/E/F/G/H=36-509.
DR   PDB; 1ZMD; X-ray; 2.08 A; A/B/C/D/E/F/G/H=36-509.
DR   PDB; 1ZY8; X-ray; 2.59 A; A/B/C/D/E/F/G/H/I/J=36-509.
DR   PDB; 2F5Z; X-ray; 2.18 A; A/B/C/D/E/F/G/H/I/J=36-509.
DR   PDB; 3RNM; X-ray; 2.40 A; A/B/C/D=36-509.
DR   PDBsum; 1ZMC; -.
DR   PDBsum; 1ZMD; -.
DR   PDBsum; 1ZY8; -.
DR   PDBsum; 2F5Z; -.
DR   PDBsum; 3RNM; -.
DR   ProteinModelPortal; P09622; -.
DR   SMR; P09622; -.
DR   BioGrid; 108082; 82.
DR   DIP; DIP-29027N; -.
DR   IntAct; P09622; 14.
DR   MINT; MINT-3007138; -.
DR   STRING; 9606.ENSP00000205402; -.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB00157; NADH.
DR   iPTMnet; P09622; -.
DR   PhosphoSitePlus; P09622; -.
DR   SwissPalm; P09622; -.
DR   BioMuta; DLD; -.
DR   DMDM; 269849557; -.
DR   REPRODUCTION-2DPAGE; IPI00015911; -.
DR   UCD-2DPAGE; P09622; -.
DR   EPD; P09622; -.
DR   MaxQB; P09622; -.
DR   PaxDb; P09622; -.
DR   PeptideAtlas; P09622; -.
DR   PRIDE; P09622; -.
DR   DNASU; 1738; -.
DR   Ensembl; ENST00000205402; ENSP00000205402; ENSG00000091140. [P09622-1]
DR   Ensembl; ENST00000417551; ENSP00000390667; ENSG00000091140. [P09622-1]
DR   Ensembl; ENST00000437604; ENSP00000387542; ENSG00000091140. [P09622-3]
DR   GeneID; 1738; -.
DR   KEGG; hsa:1738; -.
DR   UCSC; uc003vet.5; human. [P09622-1]
DR   CTD; 1738; -.
DR   DisGeNET; 1738; -.
DR   GeneCards; DLD; -.
DR   H-InvDB; HIX0006994; -.
DR   HGNC; HGNC:2898; DLD.
DR   HPA; HPA044849; -.
DR   MalaCards; DLD; -.
DR   MIM; 238331; gene.
DR   MIM; 246900; phenotype.
DR   neXtProt; NX_P09622; -.
DR   OpenTargets; ENSG00000091140; -.
DR   Orphanet; 2394; Pyruvate dehydrogenase E3 deficiency.
DR   PharmGKB; PA27352; -.
DR   eggNOG; KOG1335; Eukaryota.
DR   eggNOG; COG1249; LUCA.
DR   GeneTree; ENSGT00550000074844; -.
DR   HOGENOM; HOG000276708; -.
DR   HOVERGEN; HBG002290; -.
DR   InParanoid; P09622; -.
DR   KO; K00382; -.
DR   OMA; VYTQPEI; -.
DR   OrthoDB; EOG091G05AA; -.
DR   PhylomeDB; P09622; -.
DR   TreeFam; TF300414; -.
DR   BioCyc; MetaCyc:HS01727-MONOMER; -.
DR   BRENDA; 1.8.1.4; 2681.
DR   Reactome; R-HSA-204174; Regulation of pyruvate dehydrogenase (PDH) complex.
DR   Reactome; R-HSA-389661; Glyoxylate metabolism and glycine degradation.
DR   Reactome; R-HSA-5362517; Signaling by Retinoic Acid.
DR   Reactome; R-HSA-6783984; Glycine degradation.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   Reactome; R-HSA-70895; Branched-chain amino acid catabolism.
DR   Reactome; R-HSA-71064; Lysine catabolism.
DR   Reactome; R-HSA-71403; Citric acid cycle (TCA cycle).
DR   SABIO-RK; P09622; -.
DR   ChiTaRS; DLD; human.
DR   EvolutionaryTrace; P09622; -.
DR   GeneWiki; Dihydrolipoamide_dehydrogenase; -.
DR   GenomeRNAi; 1738; -.
DR   PRO; PR:P09622; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000091140; -.
DR   CleanEx; HS_DLD; -.
DR   ExpressionAtlas; P09622; baseline and differential.
DR   Genevisible; P09622; HS.
DR   GO; GO:0043159; C:acrosomal matrix; IEA:Ensembl.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0031514; C:motile cilium; IEA:UniProtKB-KW.
DR   GO; GO:0043209; C:myelin sheath; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0045252; C:oxoglutarate dehydrogenase complex; IEA:Ensembl.
DR   GO; GO:0045254; C:pyruvate dehydrogenase complex; IDA:MGI.
DR   GO; GO:0004148; F:dihydrolipoyl dehydrogenase activity; TAS:Reactome.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:Ensembl.
DR   GO; GO:0043544; F:lipoamide binding; IEA:Ensembl.
DR   GO; GO:0051287; F:NAD binding; IEA:Ensembl.
DR   GO; GO:0006103; P:2-oxoglutarate metabolic process; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0009083; P:branched-chain amino acid catabolic process; TAS:Reactome.
DR   GO; GO:0045454; P:cell redox homeostasis; IEA:InterPro.
DR   GO; GO:0051068; P:dihydrolipoamide metabolic process; IEA:Ensembl.
DR   GO; GO:0007369; P:gastrulation; IEA:Ensembl.
DR   GO; GO:0046487; P:glyoxylate metabolic process; TAS:Reactome.
DR   GO; GO:0009106; P:lipoate metabolic process; IEA:Ensembl.
DR   GO; GO:0006554; P:lysine catabolic process; TAS:Reactome.
DR   GO; GO:0061732; P:mitochondrial acetyl-CoA biosynthetic process from pyruvate; IC:MGI.
DR   GO; GO:0006120; P:mitochondrial electron transport, NADH to ubiquinone; IEA:Ensembl.
DR   GO; GO:0006508; P:proteolysis; IEA:Ensembl.
DR   GO; GO:0006090; P:pyruvate metabolic process; TAS:Reactome.
DR   GO; GO:0010510; P:regulation of acetyl-CoA biosynthetic process from pyruvate; TAS:Reactome.
DR   GO; GO:0042391; P:regulation of membrane potential; IEA:Ensembl.
DR   GO; GO:0048240; P:sperm capacitation; IEA:Ensembl.
DR   GO; GO:0006099; P:tricarboxylic acid cycle; TAS:Reactome.
DR   Gene3D; 3.30.390.30; -; 1.
DR   Gene3D; 3.50.50.60; -; 1.
DR   InterPro; IPR023753; FAD/NAD-binding_dom.
DR   InterPro; IPR016156; FAD/NAD-linked_Rdtase_dimer.
DR   InterPro; IPR006258; Lipoamide_DH.
DR   InterPro; IPR004099; Pyr_nucl-diS_OxRdtase_dimer.
DR   InterPro; IPR012999; Pyr_OxRdtase_I_AS.
DR   Pfam; PF07992; Pyr_redox_2; 1.
DR   Pfam; PF02852; Pyr_redox_dim; 1.
DR   SUPFAM; SSF51905; SSF51905; 1.
DR   SUPFAM; SSF55424; SSF55424; 1.
DR   TIGRFAMs; TIGR01350; lipoamide_DH; 1.
DR   PROSITE; PS00076; PYRIDINE_REDOX_1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Cell projection;
KW   Cilium; Complete proteome; Cytoplasmic vesicle; Disease mutation;
KW   Disulfide bond; FAD; Flagellum; Flavoprotein; Mitochondrion; NAD;
KW   Oxidoreductase; Phosphoprotein; Polymorphism; Redox-active center;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     35       Mitochondrion.
FT                                {ECO:0000244|PubMed:25944712}.
FT   CHAIN        36    509       Dihydrolipoyl dehydrogenase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000030295.
FT   NP_BIND      71     80       FAD.
FT   NP_BIND     183    185       FAD.
FT   NP_BIND     220    227       NAD.
FT   NP_BIND     361    364       FAD.
FT   ACT_SITE    487    487       Proton acceptor. {ECO:0000250}.
FT   BINDING      89     89       FAD.
FT   BINDING     154    154       FAD; via amide nitrogen and carbonyl
FT                                oxygen.
FT   BINDING     243    243       NAD.
FT   BINDING     278    278       NAD; via amide nitrogen and carbonyl
FT                                oxygen.
FT   BINDING     314    314       NAD; via amide nitrogen.
FT   BINDING     355    355       FAD.
FT   SITE        448    448       Important for interaction with PDHX and
FT                                activity of multienzyme pyruvate
FT                                dehydrogenase complex.
FT                                {ECO:0000269|PubMed:20385101}.
FT   SITE        473    473       Important for interaction with PDHX and
FT                                activity of multienzyme pyruvate
FT                                dehydrogenase complex.
FT                                {ECO:0000269|PubMed:20385101}.
FT   MOD_RES      66     66       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES      66     66       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     104    104       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     104    104       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     122    122       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     122    122       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     132    132       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     132    132       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     143    143       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     143    143       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     159    159       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     166    166       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     273    273       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     277    277       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     285    285       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     297    297       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6P6R2}.
FT   MOD_RES     346    346       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     410    410       N6-acetyllysine; alternate.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     410    410       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     417    417       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     420    420       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     430    430       N6-succinyllysine.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     502    502       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     505    505       N6-acetyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   MOD_RES     505    505       N6-succinyllysine; alternate.
FT                                {ECO:0000250|UniProtKB:O08749}.
FT   DISULFID     80     85       Redox-active.
FT   VAR_SEQ       1     99       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055855.
FT   VAR_SEQ     147    194       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055856.
FT   VARIANT      47     47       I -> T (in DLDD; dbSNP:rs397514651).
FT                                {ECO:0000269|PubMed:16770810}.
FT                                /FTId=VAR_076985.
FT   VARIANT      72     72       K -> E (in DLDD; reduced dihydrolipoyl
FT                                dehydrogenase activity; no effect on
FT                                interaction with PDHX;
FT                                dbSNP:rs121964987).
FT                                {ECO:0000269|PubMed:20160912,
FT                                ECO:0000269|PubMed:8506365}.
FT                                /FTId=VAR_006907.
FT   VARIANT     104    104       K -> T (in dbSNP:rs1130477).
FT                                {ECO:0000269|PubMed:3693355,
FT                                ECO:0000269|PubMed:8406489}.
FT                                /FTId=VAR_031922.
FT   VARIANT     136    136       Missing (in DLDD).
FT                                {ECO:0000269|PubMed:9540846}.
FT                                /FTId=VAR_076986.
FT   VARIANT     229    229       G -> C (in DLDD; dbSNP:rs121964990).
FT                                {ECO:0000269|PubMed:16770810,
FT                                ECO:0000269|PubMed:9934985}.
FT                                /FTId=VAR_015820.
FT   VARIANT     331    331       L -> V (in dbSNP:rs17624).
FT                                /FTId=VAR_014555.
FT   VARIANT     361    361       M -> V (in DLDD; dbSNP:rs121964993).
FT                                {ECO:0000269|PubMed:11687750}.
FT                                /FTId=VAR_076987.
FT   VARIANT     375    375       E -> K (in DLDD; loss of enzyme activity;
FT                                abolished interaction with PDHX;
FT                                dbSNP:rs121964992).
FT                                {ECO:0000269|PubMed:11687750,
FT                                ECO:0000269|PubMed:16770810,
FT                                ECO:0000269|PubMed:20160912,
FT                                ECO:0000269|PubMed:9540846}.
FT                                /FTId=VAR_076988.
FT   VARIANT     393    393       I -> T (in DLDD; dbSNP:rs121964991).
FT                                {ECO:0000269|PubMed:12925875}.
FT                                /FTId=VAR_076989.
FT   VARIANT     479    479       D -> V (in DLDD; reduced dehydrogenase
FT                                activity; increased proteolytic activity;
FT                                dbSNP:rs397514649).
FT                                {ECO:0000269|PubMed:10448086,
FT                                ECO:0000269|PubMed:17404228}.
FT                                /FTId=VAR_076990.
FT   VARIANT     482    482       R -> G (in DLDD; reduced enzyme activity;
FT                                dbSNP:rs397514650).
FT                                /FTId=VAR_076991.
FT   VARIANT     488    488       P -> L (in DLDD; no effect on interaction
FT                                with PDHX; dbSNP:rs121964988).
FT                                {ECO:0000269|PubMed:20160912,
FT                                ECO:0000269|PubMed:8506365}.
FT                                /FTId=VAR_006908.
FT   VARIANT     495    495       R -> G (in DLDD; loss of enzyme activity;
FT                                reduced interaction with PDHX;
FT                                dbSNP:rs121964989).
FT                                {ECO:0000269|PubMed:16442803,
FT                                ECO:0000269|PubMed:20160912,
FT                                ECO:0000269|PubMed:8968745}.
FT                                /FTId=VAR_015821.
FT   MUTAGEN      89     89       K->E: Abolishes dihydrolipoyl
FT                                dehydrogenase activity. Does not affect
FT                                interaction with PDHX.
FT                                {ECO:0000269|PubMed:20160912}.
FT   MUTAGEN     383    383       H->A: Reduces dihydrolipoyl dehydrogenase
FT                                activity. {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     383    383       H->L: Reduces dihydrolipoyl dehydrogenase
FT                                activity. {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     448    448       D->A: Reduces interaction with PDHX.
FT                                Inhibits multienzyme pyruvate
FT                                dehydrogenase complex activity. Does not
FT                                affect dihydrolipoyl dehydrogenase
FT                                activity. {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     448    448       D->N: Does not affect dihydrolipoyl
FT                                dehydrogenase activity.
FT                                {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     466    466       E->A: Decreases dehydrogenase activity.
FT                                Loss of proteolytic activity.
FT                                {ECO:0000269|PubMed:17404228}.
FT   MUTAGEN     473    473       Y->A: Reduces interaction with PDHX.
FT                                Inhibits multienzyme pyruvate
FT                                dehydrogenase complex activity. Does not
FT                                affect dihydrolipoyl dehydrogenase
FT                                activity. {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     473    473       Y->F: Does not affect dihydrolipoyl
FT                                dehydrogenase activity.
FT                                {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     473    473       Y->H: Reduces interaction with PDHX.
FT                                Inhibits multienzyme pyruvate
FT                                dehydrogenase complex activity. Does not
FT                                affect dihydrolipoyl dehydrogenase
FT                                activity. {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     482    482       R->A: Does not affect dihydrolipoyl
FT                                dehydrogenase activity.
FT                                {ECO:0000269|PubMed:20385101}.
FT   MUTAGEN     482    482       R->M: Does not affect interaction with
FT                                PDHX. {ECO:0000269|PubMed:20160912}.
FT   MUTAGEN     485    485       H->A: Loss of dehydrogenase activity.
FT                                Increases proteolytic activity.
FT                                {ECO:0000269|PubMed:17404228}.
FT   MUTAGEN     491    491       S->A: Loss of proteolytic activity. Does
FT                                not affect dehydrogenase activity.
FT                                {ECO:0000269|PubMed:17404228}.
FT   MUTAGEN     492    492       E->Q: Reduces dihydrolipoyl dehydrogenase
FT                                activity. Does not affect interaction
FT                                with PDHX. {ECO:0000269|PubMed:20160912}.
FT   MUTAGEN     505    505       K->M: Reduces dihydrolipoyl dehydrogenase
FT                                activity. Does not affect interaction
FT                                with PDHX. {ECO:0000269|PubMed:20160912}.
FT   CONFLICT    154    154       G -> R (in Ref. 2; AAA35764).
FT                                {ECO:0000305}.
FT   CONFLICT    209    209       L -> F (in Ref. 5; BAD92940).
FT                                {ECO:0000305}.
FT   CONFLICT    493    493       A -> AEA (in Ref. 3; AAB01381).
FT                                {ECO:0000305}.
FT   STRAND       40     47       {ECO:0000244|PDB:1ZMD}.
FT   HELIX        51     62       {ECO:0000244|PDB:1ZMD}.
FT   STRAND       67     71       {ECO:0000244|PDB:1ZMD}.
FT   STRAND       73     77       {ECO:0000244|PDB:1ZMD}.
FT   HELIX        78     83       {ECO:0000244|PDB:1ZMD}.
FT   HELIX        85    102       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       105    108       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      111    114       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      116    118       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       120    144       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      148    158       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      161    165       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      171    181       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      185    187       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      197    201       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       203    206       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      214    219       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       223    234       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      238    242       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      244    249       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       255    267       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      271    273       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      275    283       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      289    295       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      302    311       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      315    317       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       324    327       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      350    352       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       354    356       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      357    359       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       363    377       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       386    388       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      391    393       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      395    403       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       406    412       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      416    422       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       423    425       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       427    431       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      438    444       {ECO:0000244|PDB:1ZMD}.
FT   TURN        445    447       {ECO:0000244|PDB:1ZMD}.
FT   STRAND      449    457       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       460    473       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       477    482       {ECO:0000244|PDB:1ZMD}.
FT   HELIX       491    503       {ECO:0000244|PDB:1ZMD}.
SQ   SEQUENCE   509 AA;  54177 MW;  7613492C516F3835 CRC64;
     MQSWSRVYCS LAKRGHFNRI SHGLQGLSAV PLRTYADQPI DADVTVIGSG PGGYVAAIKA
     AQLGFKTVCI EKNETLGGTC LNVGCIPSKA LLNNSHYYHM AHGKDFASRG IEMSEVRLNL
     DKMMEQKSTA VKALTGGIAH LFKQNKVVHV NGYGKITGKN QVTATKADGG TQVIDTKNIL
     IATGSEVTPF PGITIDEDTI VSSTGALSLK KVPEKMVVIG AGVIGVELGS VWQRLGADVT
     AVEFLGHVGG VGIDMEISKN FQRILQKQGF KFKLNTKVTG ATKKSDGKID VSIEAASGGK
     AEVITCDVLL VCIGRRPFTK NLGLEELGIE LDPRGRIPVN TRFQTKIPNI YAIGDVVAGP
     MLAHKAEDEG IICVEGMAGG AVHIDYNCVP SVIYTHPEVA WVGKSEEQLK EEGIEYKVGK
     FPFAANSRAK TNADTDGMVK ILGQKSTDRV LGAHILGPGA GEMVNEAALA LEYGASCEDI
     ARVCHAHPTL SEAFREANLA ASFGKSINF
//
